AGRX(Delisted)
Agile Therapeutics·NASDAQ
--
--(--)
AGRX fundamentals
Agile Therapeutics (AGRX) released its earnings on Nov 6, 2017: revenue was -- (YoY 0.00%), beat estimates; EPS was -- (YoY 0.00%), met estimates.
Revenue / YoY
--
0.00%
EPS / YoY
--
0.00%
Report date
Nov 6, 2017
EPS
Revenue
Revenue & Expenses
AGRX has released its 2023 Q3 earnings report, with revenue of 6.66M, reflecting a YoY change of 121.92%, and net profit of -799.00K, showing a YoY change of 86.53%. The Sankey diagram below clearly presents AGRX's revenue sources and cost distribution.
Key Indicators
Agile Therapeutics (AGRX) key financial stats and ratios, covering profitability, financial health, and leverage.
Agile Therapeutics (AGRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Agile Therapeutics (AGRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Agile Therapeutics (AGRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Agile Therapeutics (AGRX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Agile Therapeutics (AGRX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
No Data
